| Market Capitalization (Millions $) |
273 |
| Shares
Outstanding (Millions) |
61 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
49 |
| Net Income (TTM) (Millions $) |
-172 |
| Cash Flow (TTM) (Millions $) |
-15 |
| Capital Exp. (TTM) (Millions $) |
0 |
Sutro Biopharma Inc
Sutro Biopharma Inc is a clinical-stage company that specializes in developing next-generation antibody-drug conjugate (ADC) therapies for the treatment of cancer. The company utilizes its proprietary technology called cell-free protein synthesis to design and develop novel ADCs with improved efficacy and safety profiles.
Sutro Biopharma's platform enables them to rapidly discover and manufacture ADCs in a highly efficient manner, resulting in a faster timeline from discovery to development. The company has a diverse pipeline of potential therapies targeting various types of cancer, including solid tumors and hematologic malignancies.
The goal of Sutro Biopharma is to transform the treatment landscape for cancer patients by delivering potent and targeted therapies that have the potential to improve outcomes and minimize side effects. They collaborate with pharmaceutical companies and academic institutions to advance their pipeline and leverage their technology for the development of novel therapies.
Sutro Biopharma is committed to innovation, and their unique approach to ADC development sets them apart in the biopharmaceutical industry. With a team of experienced scientists and researchers, the company aims to bring transformative therapies to patients in need.
Company Address: 111 Oyster Point Blvd South San Francisco 94080 CA
Company Phone Number: 881-6500 Stock Exchange / Ticker: NASDAQ STRO
|
